摘要
多形性胶质母细胞瘤(GBM)作为最严重的脑肿瘤,尽管在癌症治疗方面取得了重大进展,但目前的护理标准并不充分。在接受目前标准治疗(包括手术、放疗和化疗)的患者中,GBM的总生存期(OS)小于一年。GBM的高死亡率是由于它的侵袭性,包括加速生长,解除细胞凋亡,以及侵入周围组织。因此,了解GBM的分子发病机制对于识别、设计和重新利用未来治疗方法中的潜在药物至关重要。近几十年来,在星形胶质细胞中发现了几种神经递质,特别是P物质(SP),它是神经肽速激肽家族中的一种十肽。在与神经激肽-1受体(NK-1R)结合后,SP控制癌细胞生长,发挥抗凋亡作用,刺激细胞侵袭/转移,并激活血管生成。由于SP/NK-1R信号通路在许多癌症中是一个生长驱动因素,这一潜在机制被提出作为治疗GBM的额外靶点。在评估了SP及其NK-1R抑制剂在肿瘤细胞中的功能后,我们推荐一种独特且有前景的治疗GBM患者的方法。
关键词: 多形性胶质母细胞瘤,凋亡,P物质,神经激肽1受体(NK-1R), GBM
Current Medicinal Chemistry
Title:Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Volume: 28 Issue: 24
关键词: 多形性胶质母细胞瘤,凋亡,P物质,神经激肽1受体(NK-1R), GBM
摘要: The current standard of care in glioblastoma multiforme (GBM), as the most morbid brain tumor, is not adequate, despite substantial progress in cancer therapy. Among patients receiving current standard treatments, including surgery, irradiation, and chemotherapy, the overall survival (OS) period with GBM is less than one year. The high mortality frequency of GBM is due to its aggressive nature, including accelerated growth, deregulated apoptosis, and invasion into surrounding tissues. The understanding of the molecular pathogenesis of GBM is, therefore, crucial for identifying, designing, and repurposing potential agents in future therapeutic approaches. In recent decades, it has been apparent that several neurotransmitters, specifically substance P (SP), an undecapeptide in the family of neuropeptides tachykinins, are found in astrocytes. After binding to the neurokinin-1 receptor (NK-1R), the SP controls cancer cell growth, exerts antiapoptotic impacts, stimulates cell invasion/metastasis, and activates vascularization. Since SP/NK-1R signaling pathway is a growth driver in many cancers, this potential mechanism is proposed as an additional target for treating GBM. Following an evaluation of the function of both SP and its NK-1R inhibitors in neoplastic cells, we recommend a unique and promising approach for the treatment of patients with GBM.
Export Options
About this article
Cite this article as:
Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme, Current Medicinal Chemistry 2021; 28 (24) . https://dx.doi.org/10.2174/0929867328666210113165805
DOI https://dx.doi.org/10.2174/0929867328666210113165805 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications
Current Protein & Peptide Science Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX-Tumor-Associated (Hypoxia)
Letters in Drug Design & Discovery Triazole as Potent Anti-cancer Agent- A Pharmacophoric Scaffold
Current Cancer Therapy Reviews Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets The Mad2-Binding Protein p31<sup>comet</sup> as a Potential Target for Human Cancer Therapy
Current Cancer Drug Targets Adenovirus As An Integrating Vector
Current Gene Therapy Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Chemoradiation for Glioblastoma
Current Drug Therapy Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets